Bone Neoplasms
📧 Sign up to get email alerts when something new happens for Bone Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
Authorised new medicine Bilprevda (denosumab) by Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone and bone neoplasms.
-
EMA approval · 2026-08-24EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH
Bomyntra (denosumab) has been authorised by the EMA for indications related to bone neoplasms including Giant Cell Tumor of Bone; MAH is Fre…
-
EMA approval · 2026-04-16EMA Authorised: Enwylma — Zentiva k.s.
The EMA authorised Enwylma from Zentiva k.s. for neoplasms of bone tissue, including giant cell tumor of bone, with the decision dated 15 Ap…
-
EMA approval · 2026-03-27EMA Authorised: Vevzuo (denosumab) — Biosimilar Collaborations Ireland Limited
The EMA authorised Vevzuo, a denosumab biosimilar, for bone neoplasms including Giant Cell Tumor of Bone.
-
EMA approval · 2026-03-19EMA Authorised: Xgeva (denosumab) — Amgen Europe B.V.
European Medicines Agency authorised Xgeva (denosumab) for giant cell tumor of bone, expanding its indications for this bone neoplasm. Decis…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-19EMA Authorised: Osenvelt (denosumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Osenvelt (denosumab) by Celltrion Healthcare Hungary Kft. for Giant Cell Tumor of Bone and other bone neoplasms.
-
EMA approval · 2026-03-02EMA Authorised: Xbonzy (denosumab) — Reddy Holding GmbH
The EMA authorised Xbonzy (denosumab) by Reddy Holding GmbH for the treatment of giant cell tumor of bone and other bone neoplasms.
-
EMA approval · 2026-01-20EMA Authorised: Degevma (denosumab) — Teva GmbH
EMA authorised Degevma (denosumab) by Teva GmbH for Giant Cell Tumor of Bone, expanding treatment options for this rare bone neoplasm.
-
EMA approval · 2026-01-14EMA Authorised: Zvogra (denosumab) — Stada Arzneimittel AG
The EMA authorised Zvogra (denosumab) for the treatment of giant cell tumor of bone and bone neoplasms.
-
EMA approval · 2026-01-09EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o
The EMA authorised Bilprevda (denosumab) from Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone. This expands denosumab's use to bone ne…
-
EMA approval · 2025-11-24EMA Authorised: Denbrayce (denosumab) — Mabxience Research SL
The EMA has authorised Denbrayce (denosumab) from Mabxience Research SL for the treatment of giant cell tumor of the bone. The product targe…
-
EMA approval · 2025-08-13EMA Authorised: Wyost (denosumab) — Sandoz GmbH
The European Medicines Agency authorised Wyost, a denosumab medicine from Sandoz GmbH, for Giant Cell Tumor of Bone and related bone neoplas…